ProVerum Secures $80 Million Series B Financing to Advance New Treatment for BPH
Summary
ProVerum Limited raised $80 million in a Series B equity financing led by MVM Partners, with participation from OrbiMed, ISIF, and existing investors. The company develops the ProVee System, a minimally invasive device for treating benign prostatic hyperplasia. ProVerum said it will use the proceeds to prepare for commercialization of the treatment. The company also added new board members from MVM Partners and OrbiMed as part of the financing round.
Funding
Amount
$80.0M
Total raised
Date
August 25, 2025
Announcement date
Investors
Lightstone Ventures, Atlantic Bridge, MVM Life Science Partners LLP, OrbiMed, Ireland Strategic Investment Fund
Lead investors
Company
proverummedical.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected